Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 5;14:5415. doi: 10.1038/s41467-023-41218-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A ELISA for IFN-β content in the supernatant after knocked-down indicated genes and cultured in CM or Trp-free medium. P value compared to si-scrRNA in Trp-free medium group. B Luciferase reporter assays for IFN-β after transfected with luciferase reporters for cGAS alone with STING. C ELISA for IFN-β content in the supernatant after Trp supplementation and treated with RT. D Immunoassay for representative cGAS-STING related genes expression after treated with cisplatin or RT under indicated medium. E Immunoassay for representative cGAS-STING related genes expression after Trp supplementation and treated with cisplatin. F Immunoassay for representative cGAS-STING related genes expression after treated with oxaliplatin under indicated medium. G Immunoassay for H2A.X expression after cultured in CM or Trp-free medium and treated with cisplatin. H Representative immunofluorescent staining images for dsDNA expression and location after treated with cisplatin or RT under indicated medium (n = 20 cells per group). Scale bar 20 μm. I Immunoassay for cGAS-STING-related genes expression after treated with cGAMP under indicated medium. J ELISA for IFN-β content in the supernatant after transfected with STING under the indicated medium. K Immunoassay of pSTING and STING expression in MB49-bearing mice after indicated treatment (n = 6). L Effect of Sting knocked-out combined cisplatin and Trp-free feed on MB49 growth (n = 6) (Mean ± SEM). M Effect of Sting knocked-out combined cisplatin and Trp-free feed on bladder orthotopic MB49 growth (n = 6). N Effect of Trp-free feed combined diABZI on MB49 growth (n = 6) (Mean ± SEM). P value by One-way ANOVA (A–C, J, M, N). P value by two-tailed Wilcoxon (H, K, L). All p value < 0.05 as statistic difference. Error bars represent Mean ± SD, unless otherwise indicated. Three biologically independent experiments were performed (A–G, I, J). Source data are provided as a Source Data file.